Cargando…
Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations
SIMPLE SUMMARY: Over the past decade, randomized controlled trials as an established instrument of evidence-based medicine have contributed fundamentally to the development and approval of new substances. However, it has been frequently shown that less than 5% of adult cancer patients enroll in clin...
Autores principales: | Boquoi, Amelie, Rings, Veronika, Mohring, Annemarie, Savickaite, Ingrida, Zukovs, Romans, Strapatsas, Judith, Nachtkamp, Kathrin, Kobbe, Guido, Germing, Ulrich, Fenk, Roland |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106039/ https://www.ncbi.nlm.nih.gov/pubmed/35565276 http://dx.doi.org/10.3390/cancers14092147 |
Ejemplares similares
-
Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis
por: Boquoi, A., et al.
Publicado: (2022) -
18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?
por: Zukovs, Romans, et al.
Publicado: (2022) -
Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)
por: Boquoi, Amelie, et al.
Publicado: (2023) -
Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
por: Kasprzak, Annika, et al.
Publicado: (2021) -
Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients
por: Strapatsas, Judith, et al.
Publicado: (2021)